Therapeutic Response

CD19 + and not BCR::ABL1 status confers therapeutic sensitivity to Blinatumomab in patients with Acute Lymphoblastic Leukemia.

Statements

Source and description
Blincyto (blinatumomab) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to blinatumomab for the treatment of adult and pediatric patients one month and older with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multiphase chemotherapy.
Blincyto (blinatumomab) [product information]. EMA. The European Medicines Agency (EMA) has authorized Blincyto (blinatumomab) as a monotherapy for the treatment of adult patients with CD19 positive relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL). Patients with Philadelphia chromosome positive B-precursor ALL should have failed treatment with at least 2 tyrosine kinase inhibitors (TKIs) and have no alternative treatment options.
Blincyto (blinatumomab) [product information]. EMA. The European Medicines Agency (EMA) has authorized Blincyto (blinatumomab) as a monotherapy for the treatment of adult patients with Philadelphia chromosome negative CD19 positive B-cell precusor ALL in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.
Blincyto (blinatumomab) [product information]. EMA. The European Medicines Agency (EMA) has authorized Blincyto (blinatumomab) as a monotherapy for the treatment of pediatric patients aged 1 month or older with Philidelphia chromosome negative CD19 positive B-cell precursor acute lymphoblastic leukemia (ALL) which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic hematopoietic stem cell transplants.
Blincyto (blinatumomab) [product information]. EMA. The European Medicines Agency (EMA) has authorized Blincyto (blinatumomab) as a monotherapy for the treatment of pediatric patients aged 1 month or older with high-risk first relapsed Philidelphia chromosome negative CD19 positive B-cell precursor ALL as part of the consolidation therapy.
Blincyto (blinatumomab) [product information]. EMA. The European Medicines Agency (EMA) has authorized Blincyto (blinatumomab) as a monotherapy treatment option as part of consolidation therapy for the treatment of adult patients with newly diagnosed Philidelphia chromosome negative CD19 positive B-cell precursor acute lymphoblastic leukaemia (ALL).